UY27969A1 - Formulaciones que comprenden un compuesto de indolinona - Google Patents

Formulaciones que comprenden un compuesto de indolinona

Info

Publication number
UY27969A1
UY27969A1 UY27969A UY27969A UY27969A1 UY 27969 A1 UY27969 A1 UY 27969A1 UY 27969 A UY27969 A UY 27969A UY 27969 A UY27969 A UY 27969A UY 27969 A1 UY27969 A1 UY 27969A1
Authority
UY
Uruguay
Prior art keywords
formulations
indolinone
indolinone compound
formulation
parenteral
Prior art date
Application number
UY27969A
Other languages
English (en)
Inventor
Paolo Gatti
Original Assignee
Pharmacia Itala S P A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31994326&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY27969(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia Itala S P A filed Critical Pharmacia Itala S P A
Publication of UY27969A1 publication Critical patent/UY27969A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención presenta formulaciones de indolinonas. La formulación es adecuada para administración parenteral u oral, en donde la formulación comprende una indolinona y un vehículo aceptable para uso farmacéutico para la misma. Las formulaciones y los compuestos propiamente dichos son útiles para el tratamiento de trastornos relacionados con proteína quinasas.
UY27969A 2002-09-10 2003-09-10 Formulaciones que comprenden un compuesto de indolinona UY27969A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42113302P 2002-09-10 2002-09-10

Publications (1)

Publication Number Publication Date
UY27969A1 true UY27969A1 (es) 2004-04-30

Family

ID=31994326

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27969A UY27969A1 (es) 2002-09-10 2003-09-10 Formulaciones que comprenden un compuesto de indolinona

Country Status (31)

Country Link
US (1) US20040229930A1 (es)
EP (1) EP1536783B2 (es)
JP (1) JP2006503032A (es)
KR (1) KR20050059170A (es)
CN (1) CN1688304A (es)
AR (1) AR041193A1 (es)
AT (1) ATE403425T1 (es)
AU (1) AU2003280108B2 (es)
BR (1) BR0314182A (es)
CA (1) CA2498415C (es)
DE (1) DE60322720D1 (es)
DK (1) DK1536783T3 (es)
DO (1) DOP2003000708A (es)
ES (1) ES2309363T5 (es)
GT (1) GT200300193A (es)
HN (1) HN2003000272A (es)
MX (1) MXPA05002690A (es)
MY (1) MY136767A (es)
NL (1) NL1024261C (es)
NO (1) NO20051670L (es)
NZ (1) NZ538636A (es)
PA (1) PA8581801A1 (es)
PE (1) PE20040989A1 (es)
PL (1) PL375978A1 (es)
PT (1) PT1536783E (es)
RU (1) RU2005110663A (es)
SI (1) SI1536783T1 (es)
TW (1) TW200418836A (es)
UY (1) UY27969A1 (es)
WO (1) WO2004024127A2 (es)
ZA (1) ZA200501897B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06003661A (es) 2003-10-02 2006-06-05 Pharmacia & Upjohn Co Llc Sales y polimorfos de un compuesto de indolinona sustituido con pirrol.
EP1928462A1 (en) * 2005-09-20 2008-06-11 Pfizer Products Incorporated Dosage forms and methods of treatment using a tyrosine kinase inhibitor
CN101007801A (zh) * 2006-01-27 2007-08-01 上海恒瑞医药有限公司 吡咯取代的2－二氢吲哚酮衍生物、其制法与医药上的用途
TWI482772B (zh) * 2006-08-21 2015-05-01 Astrazeneca Ab 適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物
WO2008024044A1 (en) * 2006-08-21 2008-02-28 Astrazeneca Ab Compositions, suitable for oral administration, comprising a triazolo [4, 5] pyrimidin derivate
US20090004213A1 (en) 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
CA2699306A1 (en) * 2007-11-21 2009-05-28 Teva Pharmaceutical Industries Ltd. Sunitinib hemi-l-malate, polymorphs and preparation thereof, polymorphs of racemic sunitinib malate, compositins containing sunitinib base and malic acid and preparation thereof
EP2113248A1 (en) 2008-04-29 2009-11-04 Ratiopharm GmbH Pharmaceutical composition comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-,4-dimethyl-1H-pyrrole-3-carboxamide
EP2090306A1 (en) 2008-02-13 2009-08-19 Ratiopharm GmbH Pharmaceutical compositions comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
WO2009100929A1 (en) * 2008-02-13 2009-08-20 Ratiopharm Gmbh Pharmaceutical compositions comprising n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2- dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide
EP2138167A1 (en) * 2008-06-24 2009-12-30 ratiopharm GmbH Pharmaceutical composition comprising N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
US8618309B2 (en) 2008-07-24 2013-12-31 Teva Pharmaceutical Industries Ltd. Sunitinib and salts thereof and their polymorphs
CA2704448A1 (en) * 2008-09-30 2010-04-08 Teva Pharmaceutical Industries Ltd. Amorphous compositions of sunitinib base and l-malic acid
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
CN103301116A (zh) * 2012-03-16 2013-09-18 大鹏药品工业株式会社 口服医药组合物
CN105457021A (zh) 2012-05-04 2016-04-06 辉瑞公司 前列腺相关抗原及基于疫苗的免疫治疗疗法
CN104069076A (zh) * 2013-03-29 2014-10-01 浙江九洲药业股份有限公司 一种无定型的舒尼替尼与pvp的组合物
ES2715890T3 (es) 2013-11-01 2019-06-06 Pfizer Vectores de expresión de antígenos asociados a la próstata
WO2015110952A1 (en) 2014-01-21 2015-07-30 Wockhardt Limited Solid oral pharmaceutical compositions comprising ticagrelor or salt thereof
CN104829596B (zh) * 2014-02-10 2017-02-01 石家庄以岭药业股份有限公司 吡咯取代吲哚酮类衍生物、其制备方法、包含该衍生物的组合物、及其用途
EP3539536A1 (en) 2018-03-15 2019-09-18 MH10 Spolka z ograniczona odpowiedzialnoscia A pharmaceutical composition of sunitinib or its salt thereof in its polymorphic form i
KR20210113290A (ko) 2019-01-09 2021-09-15 셀진 코포레이션 (s)-4-(4-(4-(((2-(2,6-다이옥소피페리딘-3-일)-1-옥소아이소인돌린-4-일)옥시)메틸)벤질)피페라진-1-일)-3-플루오로벤조나이트릴을 포함하는 약제학적 조성물 및 이의 사용 방법
WO2022006512A1 (en) * 2020-07-02 2022-01-06 The Board Of Regents Of The University Of Texas System Methods of treatment for melanoma

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4609675A (en) * 1984-08-17 1986-09-02 The Upjohn Company Stable, high dose, high bulk density ibuprofen granulations for tablet and capsule manufacturing
US6077533A (en) * 1994-05-25 2000-06-20 Purdue Pharma L.P. Powder-layered oral dosage forms
AU1928501A (en) * 1999-11-24 2001-06-04 Sugen, Inc. Formulations for pharmaceutical agents ionizable as free acids or free bases
DE19956598A1 (de) * 1999-11-25 2001-06-13 Bosch Gmbh Robert Ventil zum Steuern von Flüssigkeiten
DE122010000004I1 (de) * 2000-02-15 2010-04-15 Sugen Inc Pyrrol substituierte indolin-2-on protein kinase inhibitoren
CA2455050C (en) * 2001-08-15 2007-02-20 Pharmacia & Upjohn Company Crystals including a malic acid salt of n-[2-(diethylamino) ethyl]-5-[(5-fluoro-2-oxo-3h-indole-3-ylidene) methyl]-2, 4-dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof
TWI259081B (en) * 2001-10-26 2006-08-01 Sugen Inc Treatment of acute myeloid leukemia with indolinone compounds

Also Published As

Publication number Publication date
ZA200501897B (en) 2005-09-07
AR041193A1 (es) 2005-05-04
CA2498415C (en) 2007-05-29
AU2003280108B2 (en) 2007-04-05
NL1024261C (nl) 2010-04-06
CN1688304A (zh) 2005-10-26
DOP2003000708A (es) 2004-03-31
DK1536783T3 (da) 2008-10-13
EP1536783B1 (en) 2008-08-06
WO2004024127A3 (en) 2004-06-03
KR20050059170A (ko) 2005-06-17
NO20051670L (no) 2005-04-04
AU2003280108A1 (en) 2004-04-30
ES2309363T3 (es) 2008-12-16
GT200300193A (es) 2004-04-29
TW200418836A (en) 2004-10-01
JP2006503032A (ja) 2006-01-26
WO2004024127A2 (en) 2004-03-25
ATE403425T1 (de) 2008-08-15
NL1024261A1 (nl) 2004-03-11
DE60322720D1 (de) 2008-09-18
US20040229930A1 (en) 2004-11-18
PL375978A1 (en) 2005-12-12
MY136767A (en) 2008-11-28
HN2003000272A (es) 2008-07-29
ES2309363T5 (es) 2011-12-07
NZ538636A (en) 2006-04-28
EP1536783A2 (en) 2005-06-08
PA8581801A1 (es) 2005-02-04
EP1536783B2 (en) 2011-08-24
MXPA05002690A (es) 2005-05-05
PT1536783E (pt) 2008-10-10
BR0314182A (pt) 2005-08-09
RU2005110663A (ru) 2005-09-10
SI1536783T1 (sl) 2008-12-31
PE20040989A1 (es) 2004-12-28
CA2498415A1 (en) 2004-03-25

Similar Documents

Publication Publication Date Title
UY27969A1 (es) Formulaciones que comprenden un compuesto de indolinona
CY1106468T1 (el) Υποκατεστημενα παραγωγα κυκλοεξανο-1,4-διαμινης
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
SV2004001690A (es) Nuevos derivados de fluoroglicosidos heterociclicos, medicamentos que contienen estos compuestos, y el uso de los mismos
AR028810A1 (es) Derivados de arilpiperazinil-ciclohexil indol, composiciones farmaceuticas que los comprenden y el uso de los mismos para la manufactura de medicamentos para el tratamiento de la depresion
CO5271700A1 (es) Composicion farmaceutica que comprende acido 3-[2,4-dimetil-5-(2-oxo-1,2-dihidro-indol-3-ilidenmetil)-1h-pirrol-3-il]-propionico, uno o mas compuestos polihidrocarbilo y un vehiculo farmaceuticamente aceptable
AR023423A1 (es) Derivados de adamantano, procedimientos para su preparacion, composicion farmaceutica, procedimiento para la preparacion de la composicion farmaceutica, yuso de dichos derivados para la manufactura de medicamentos
ECSP024399A (es) Derivados de benzotiazol
CO5590918A2 (es) Formulaciones
UY27740A1 (es) Nuevos compuestos
CY1118179T1 (el) Φαρμακευτικη συνθεση
CY1112376T1 (el) Παραγωγα 2,3,4,9-τετραϋδρο-1η-καρβαζολης ως ανταγωνιστες του υποδοχεα crth2
PA8586001A1 (es) Derivados de indol útiles para el tratamiento de enfermedades
ES2145774T3 (es) Derivados de adenosina que tienen actividad agonista en a2.
NO20055631L (no) Doseringsform inneholdende pantoprazol som aktiv ingrediens
CY1110558T1 (el) Σπειροκυκλικα παραγωγα κυκλοεξανιου
AR048912A1 (es) Inmunoglobulinas anti-nogo
ECSP088296A (es) Compuestos terapéuticos
CY1105028T1 (el) Υποκατεστημενες c-ιμιδαζο-[1,2-α]πυριδιν-3-υλο-μεθυλαμινες
HN2003000379A (es) Derivados de anilinopirazol utiles en el tratamiento de la diabetes
BR0311189A (pt) Composições farmacêuticas contendo polimorfo a de flibanserin
TNSN06012A1 (en) Emulsifying systems containing azetidine derivatives
UY28356A1 (es) Derivados de benzimidazol, composiciones que los contienen, preparaciones de los mismos y sus usos
CY1105019T1 (el) Υποκατεστημενες c-ιμιδαζο-[1,2-α]πυριδιν-3-υλο-μεθυλαμινες
CO5700723A2 (es) Uso de un derivado de amina ciclica especifico o de sus sales farmaceuticamente aceptables para tratar y prevenir la insuficiencia cardiaca

Legal Events

Date Code Title Description
VENC Patent expired

Effective date: 20230910